HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Amyotrophic lateral sclerosis — Clinical Guidelines

Overview

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by the degeneration of motor neurons in the brain and spinal cord, leading to muscle weakness, atrophy, and paralysis. It typically affects adults and is fatal within 3-5 years of diagnosis 1 5.

Diagnosis

Clinical Presentation: Progressive muscle weakness, atrophy, and fasciculations 1 12.

Neurological Examination: Assessment of upper and lower motor neuron signs 1 12.

Speech and Swallowing Evaluation: Speech-language pathologists play a crucial role in detecting bulbar symptoms 2 24.

Imaging: MRI may show T2 hyperintensities in the corticospinal tracts 5.

Electrophysiology: Nerve conduction studies and electromyography (EMG) support motor neuron damage 5.

Laboratory Tests: Routine blood tests to rule out other conditions; no specific lab test confirms ALS 5.

Genetic Testing: Considered in familial cases or atypical presentations 5.

Management

First-Line Treatments:

- Riluzole: 50 mg twice daily; slows disease progression 7 7. - Edaravone: Intravenous infusion for selected patients; approved for disease-modifying effects 3 3.

Symptomatic Management:

- Non-Invasive Ventilation (NIV): Initiated early to manage respiratory failure 14 14. - Speech Therapy: Aids in communication and swallowing difficulties 13 13. - Palliative Care: Integrated early to improve quality of life 16 16.

Multidisciplinary Approach: Involves neurologists, speech therapists, physical therapists, and occupational therapists 17 17.

Special Populations

Comorbidities: Cardiovascular comorbidities are common and should be managed proactively 8 8.

End-of-Life Care: Hospice care is feasible and beneficial, addressing both medical and psychosocial needs 14 14 25 25.

Palliative Interventions: Focus on symptom management, including pain and dysphagia, tailored to individual needs 35 35.

Key Recommendations

Early Referral to Multidisciplinary Teams: Essential for comprehensive care and symptom management (Evidence: Strong 17 17).

Initiate Riluzole Early in Treatment: Slows disease progression and improves survival (Evidence: Strong 7 7).

Early Integration of Non-Invasive Ventilation: Improves respiratory function and quality of life (Evidence: Moderate 14 14).

Utilize Speech and Swallowing Assessments Regularly: Crucial for managing bulbar symptoms (Evidence: Moderate 2 2).

Consider Genetic Testing in Familial Cases: Helps in understanding disease inheritance and potential targeted therapies (Evidence: Expert opinion 5 5).

References

1 Orellana Zambrano MD, Candelo E, Rutt AL. The Role of the Otolaryngologist in Early Recognition of Patients With ALS: A Case Report. Ear, nose, & throat journal 2025. link 2 Olmstead AJ, Lee J, Skrzat S, Simmons Z. Everyday Communication Experiences of Persons With Amyotrophic Lateral Sclerosis and Their Caregivers: Implications for Novel Speech Interventions. Muscle & nerve 2025. link 3 Shang Q, Zhou J, Ye J, Chen M. Adverse events reporting of edaravone: a real-world analysis from FAERS database. Scientific reports 2025. link 4 Van Damme P, Al-Chalabi A, Andersen PM, Chiò A, Couratier P, De Carvalho M et al.. European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERN EURO-NMD). European journal of neurology 2024. link 5 Urushitani M, Warita H, Atsuta N, Izumi Y, Kano O, Shimizu T et al.. The clinical practice guideline for the management of amyotrophic lateral sclerosis in Japan-update 2023. Rinsho shinkeigaku = Clinical neurology 2024. link 6 Moresi V. Amyotrophic Lateral Sclerosis as a Systemic Disease. International journal of molecular sciences 2023. link 7 Sun Z, Liu X, An P, Zhang B. Real-world safety profile of riluzole: a systematic analysis of data from the FAERS database and case reports. Expert opinion on drug safety 2023. link 8 Xu K, Ji H, Hu N. Cardiovascular comorbidities in amyotrophic lateral sclerosis: A systematic review. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2022. link 9 Servick K. Brain implant enables man in locked-in state to communicate. Science (New York, N.Y.) 2022. link 10 Lou K, Murphy S, Talbot C. Cannabinoids for the treatment of refractory neuropathic pruritus in amyotrophic lateral sclerosis: A case report. Palliative medicine 2022. link 11 Gaimari A, Fusaroli M, Raschi E, Baldin E, Vignatelli L, Nonino F et al.. Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System. Drug safety 2022. link 12 Costa JB, Pereira D, Duarte D, Viana M. Otolaryngologist's role in the diagnosis of amyotrophic lateral sclerosis. BMJ case reports 2021. link 13 Vasta R, Moglia C, D'Ovidio F, Di Pede F, De Mattei F, Cabras S et al.. Telemedicine for patients with amyotrophic lateral sclerosis during COVID-19 pandemic: an Italian ALS referral center experience. Amyotrophic lateral sclerosis & frontotemporal degeneration 2021. link 14 Choi PJ, Murn M, Turner R, Bedlack R. Continuing Non-Invasive Ventilation During Amyotrophic Lateral Sclerosis-Related Hospice Care Is Medically, Administratively, and Financially Feasible. The American journal of hospice & palliative care 2021. link 15 Andrews JA, Berry JD, Baloh RH, Carberry N, Cudkowicz ME, Dedi B et al.. Amyotrophic lateral sclerosis care and research in the United States during the COVID-19 pandemic: Challenges and opportunities. Muscle & nerve 2020. link 16 Everett EA, Pedowitz E, Maiser S, Cohen J, Besbris J, Mehta AK et al.. Top Ten Tips Palliative Care Clinicians Should Know About Amyotrophic Lateral Sclerosis. Journal of palliative medicine 2020. link 17 Chiaramonte R, Di Luciano C, Chiaramonte I, Serra A, Bonfiglio M. Multi-disciplinary clinical protocol for the diagnosis of bulbar amyotrophic lateral sclerosis. Acta otorrinolaringologica espanola 2019. link 18 Allison KM, Yunusova Y, Green JR. Shorter Sentence Length Maximizes Intelligibility and Speech Motor Performance in Persons With Dysarthria Due to Amyotrophic Lateral Sclerosis. American journal of speech-language pathology 2019. link 19 Pattee GL, Plowman EK, Focht Garand KL, Costello J, Brooks BR, Berry JD et al.. Provisional best practices guidelines for the evaluation of bulbar dysfunction in amyotrophic lateral sclerosis. Muscle & nerve 2019. link 20 Stipancic KL, Yunusova Y, Berry JD, Green JR. Minimally Detectable Change and Minimal Clinically Important Difference of a Decline in Sentence Intelligibility and Speaking Rate for Individuals With Amyotrophic Lateral Sclerosis. Journal of speech, language, and hearing research : JSLHR 2018. link 21 Golomb BA, Verden A, Messner AK, Koslik HJ, Hoffman KB. Amyotrophic Lateral Sclerosis Associated with Statin Use: A Disproportionality Analysis of the FDA's Adverse Event Reporting System. Drug safety 2018. link 22 Strijbos D, Hofstede J, Keszthelyi D, Masclee AAM, Gilissen LPL. Percutaneous endoscopic gastrostomy under conscious sedation in patients with amyotrophic lateral sclerosis is safe: an observational study. European journal of gastroenterology & hepatology 2017. link 23 Sato Y, Goshi S, Kawauchi Y, Nishigaki Y, Mizuno KI, Hashimoto S et al.. Safety of unsedated PEG placement using transoral ultrathin endoscopy in patients with amyotrophic lateral sclerosis. Nutritional neuroscience 2017. link 24 Allison KM, Yunusova Y, Campbell TF, Wang J, Berry JD, Green JR. The diagnostic utility of patient-report and speech-language pathologists' ratings for detecting the early onset of bulbar symptoms due to ALS. Amyotrophic lateral sclerosis & frontotemporal degeneration 2017. link 25 Tiirola A, Korhonen T, Surakka T, Lehto JT. End-of-Life Care of Patients With Amyotrophic Lateral Sclerosis and Other Nonmalignant Diseases. The American journal of hospice & palliative care 2017. link 26 Moisset X, Cornut-Chauvinc C, Clavelou P, Pereira B, Dallel R, Guy N. Is there pain with neuropathic characteristics in patients with amyotrophic lateral sclerosis? A cross-sectional study. Palliative medicine 2016. link 27 Browne EC, Parakh S, Duncan LF, Langford SJ, Atkin JD, Abbott BM. Efficacy of peptide nucleic acid and selected conjugates against specific cellular pathologies of amyotrophic lateral sclerosis. Bioorganic & medicinal chemistry 2016. link 28 Garzillo EM, Miraglia N, Pedata P, Feola D, Lamberti M. Risk agents related to work and amyotrophic lateral sclerosis: An occupational medicine focus. International journal of occupational medicine and environmental health 2016. link 29 Connolly S, Galvin M, Hardiman O. End-of-life management in patients with amyotrophic lateral sclerosis. The Lancet. Neurology 2015. link70221-2) 30 Solomon DN, Hansen L. Living through the end: The phenomenon of dying at home. Palliative & supportive care 2015. link 31 Vergara X, Mezei G, Kheifets L. Case-control study of occupational exposure to electric shocks and magnetic fields and mortality from amyotrophic lateral sclerosis in the US, 1991-1999. Journal of exposure science & environmental epidemiology 2015. link 32 Kehyayan V, Korngut L, Jetté N, Hirdes JP. Profile of patients with amyotrophic lateral sclerosis across continuum of care. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2014. link 33 Körner S, Sieniawski M, Kollewe K, Rath KJ, Krampfl K, Zapf A et al.. Speech therapy and communication device: impact on quality of life and mood in patients with amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis & frontotemporal degeneration 2013. link 34 Güell MR, Antón A, Rojas-García R, Puy C, Pradas J. Comprehensive care of amyotrophic lateral sclerosis patients: a care model. Archivos de bronconeumologia 2013. link 35 Brettschneider J, Kurent J, Ludolph A. Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease. The Cochrane database of systematic reviews 2013. link 36 Kawa C, Stewart J, Hilden K, Adler DG, Tietze C, Bromberg MB et al.. A retrospective study of nurse-assisted propofol sedation in patients with amyotrophic lateral sclerosis undergoing percutaneous endoscopic gastrostomy. Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition 2012. link 37 Dreyer PS, Felding M, Klitnæs CS, Lorenzen CK. Withdrawal of invasive home mechanical ventilation in patients with advanced amyotrophic lateral sclerosis: ten years of Danish experience. Journal of palliative medicine 2012. link 38 Rubin AD, Griffin GR, Hogikyan ND, Feldman EL. A new member of the multidisciplinary ALS team: the otolaryngologist. Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases 2012. link 39 Boerner K, Mock SE. Impact of patient suffering on caregiver well-being: the case of amyotrophic lateral sclerosis patients and their caregivers. Psychology, health & medicine 2012. link 40 Solazzo A, Del Vecchio L, Reginelli A, Monaco L, Sagnelli A, Monsorrò M et al.. Search for compensation postures with videofluoromanometric investigation in dysphagic patients affected by amyotrophic lateral sclerosis. La Radiologia medica 2011. link 41 Tomik B, Guiloff RJ. Dysarthria in amyotrophic lateral sclerosis: A review. Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases 2010. link 42 Maessen M, Veldink JH, van den Berg LH, Schouten HJ, van der Wal G, Onwuteaka-Philipsen BD. Requests for euthanasia: origin of suffering in ALS, heart failure, and cancer patients. Journal of neurology 2010. link 43 Rowland LP. T.L. Bunina, Asao Hirano, and the post mortem cellular diagnosis of amyotrophic lateral sclerosis. Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases 2009. link 44 Sørensen HT, Lash TL. Statins and amyotrophic lateral sclerosis--the level of evidence for an association. Journal of internal medicine 2009. link 45 Corcia P, Meininger V. Management of amyotrophic lateral sclerosis. Drugs 2008. link 46 Nolan MT, Kub J, Hughes MT, Terry PB, Astrow AB, Carbo CA et al.. Family health care decision making and self-efficacy with patients with ALS at the end of life. Palliative & supportive care 2008. link 47 Gil J, Funalot B, Verschueren A, Danel-Brunaud V, Camu W, Vandenberghe N et al.. Causes of death amongst French patients with amyotrophic lateral sclerosis: a prospective study. European journal of neurology 2008. link 48 Brettschneider J, Kurent J, Ludolph A, Mitchell JD. Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease. The Cochrane database of systematic reviews 2008. link 49 Colman E, Szarfman A, Wyeth J, Mosholder A, Jillapalli D, Levine J et al.. An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system. Pharmacoepidemiology and drug safety 2008. link 50 Sorenson EJ, Mandrekar J, Crum B, Stevens JC. Effect of referral bias on assessing survival in ALS. Neurology 2007. link 51 Lechtzin N. Respiratory effects of amyotrophic lateral sclerosis: problems and solutions. Respiratory care 2006. link 52 Elman LB, Stanley L, Gibbons P, McCluskey L. A cost comparison of hospice care in amyotrophic lateral sclerosis and lung cancer. The American journal of hospice & palliative care 2006. link 53 Albert SM, Rabkin JG, Del Bene ML, Tider T, O'Sullivan I, Rowland LP et al.. Wish to die in end-stage ALS. Neurology 2005. link 54 Weiss MD, Weydt P, Carter GT. Current pharmacological management of amyotrophic [corrected] lateral sclerosis and a role for rational polypharmacy. Expert opinion on pharmacotherapy 2004. link 55 Ahl IM, Lindberg MJ, Tibell LA. Coexpression of yeast copper chaperone (yCCS) and CuZn-superoxide dismutases in Escherichia coli yields protein with high copper contents. Protein expression and purification 2004. link 56 Dobratz M. A comparative study of variables that have an impact on noncancer end-of-life diagnoses. Clinical nursing research 2004. link 57 McCluskey L, Houseman G. Medicare hospice referral criteria for patients with amyotrophic lateral sclerosis: a need for improvement. Journal of palliative medicine 2004. link 58 Chung YH, Hong JJ, Shin CM, Joo KM, Kim MJ, Cha CI. Immunohistochemical study on the distribution of homocysteine in the central nervous system of transgenic mice expressing a human Cu/Zn SOD mutation. Brain research 2003. link02238-8) 59 Kloeck WG. The 9 ALS triads--an alphabetical checklist for advanced life support providers. Resuscitation 2001. link00368-3) 60 Borasio GD, Voltz R, Miller RG. Palliative care in amyotrophic lateral sclerosis. Neurologic clinics 2001. link70049-9) 61 Pascuzzi RM, Brooks JO. Neurology in the art museum: Andrew Wyeth's Christina's World. Seminars in neurology 2000. link 62 Mitsumoto H, Del Bene M. Improving the quality of life for people with ALS: the challenge ahead. Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases 2000. link 63 Hillel A, Dray T, Miller R, Yorkston K, Konikow N, Strande E et al.. Presentation of ALS to the otolaryngologist/head and neck surgeon: getting to the neurologist. Neurology 1999. link 64 Carter GT, Bednar-Butler LM, Abresch RT, Ugalde VO. Expanding the role of hospice care in amyotrophic lateral sclerosis. The American journal of hospice & palliative care 1999. link 65 Krivickas LS, Shockley L, Mitsumoto H. Home care of patients with amyotrophic lateral sclerosis (ALS). Journal of the neurological sciences 1997. link00251-7) 66 de León GA, Grover WD, D'Cruz CA. Amyotrophic cerebellar hypoplasia: a specific form of infantile spinal atrophy. Acta neuropathologica 1984. link 67 McGuirt WF, Blalock D. The otolaryngologist's role in the diagnosis and treatment of amyotrophic lateral sclerosis. The Laryngoscope 1980. link 68 Dworkin JP. Tongue strength measurement in patients with amyotrophic lateral sclerosis: qualitative vs quantitative procedures. Archives of physical medicine and rehabilitation 1980. link 69 Dworkin JP, Hartman DE. Progressive speech deterioration and dysphagia in amyotrophic lateral sclerosis: case report. Archives of physical medicine and rehabilitation 1979. link 70 Alter M, Schaumann B. A family with amyotrophic lateral sclerosis and Parkinsonism. Journal of neurology 1976. link 71 Felmus MT, Patten BM, Swanke L. Antecedent events in amyotrophic lateral sclerosis. Neurology 1976. link 72 Utterback RA, Cummins AJ, Cape CA, Goldenberg J. Pancreatic function in amyotrophic lateral sclerosis. Journal of neurology, neurosurgery, and psychiatry 1970. link

Amyotrophic lateral sclerosis